Epithelial Ovarian Cancer Clinical Trials

17 studies are recruiting for epithelial ovarian cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

   This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Advent Health, Orlando, Florida

   Locations

   9 in total

   Run by

   Imunon

   See if you can join NCT06915025 on ClinicalTrials.gov

2. A Study of Isoquercetin in People With Ovarian Cancer

   The purpose of this study is to test whether isoquercetin can reduce markers in the blood that may indicate the risk of blood clots in people with ovarian cancer. The effects of isoquercetin will be compared with those of a placebo.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey

   Locations

   8 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07303894 on ClinicalTrials.gov

3. A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous …

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Alabama at Birmingham (UAB) Hospital /ID# 274793, Birmingham, Alabama

   Locations

   70 in total

   Run by

   AbbVie

   See if you can join NCT06890338 on ClinicalTrials.gov

4. Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian Cancer

   The primary objectives of the study are: 1. To delineate commonly utilized tumor metabolic alterations in ovarian cancer. These metabolic alterations will be explored for potentially targetable pathways to restore chemotherapy responsiveness. 2. To define the relationship between whole-body metabol…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Tennessee Medical Center - Knoxville, Knoxville, Tennessee

   Run by

   University of Tennessee Graduate School of Medicine

   See if you can join NCT07764133 on ClinicalTrials.gov

5. Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer

   The goal of this clinical trial is to see if timed fasting (periods of time that you don't eat) in participants who are receiving chemotherapy prior to surgery is achievable, safe and can improve quality of life, symptoms and outcomes (results) compared to participants who receive standard dietary …

   Stage

   Not phased

   Ages

   18 and older

   Site

   Department of Subspecialty Care for Women's Health Women's Health; Division of Gynecologic Oncology, Case Comprehensive Cancer Center, Cleveland, Ohio

   Run by

   Case Comprehensive Cancer Center

   See if you can join NCT06386887 on ClinicalTrials.gov

6. AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

   The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FRα levels.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Birmingham, Alabama

   Locations

   299 in total

   Run by

   AstraZeneca

   See if you can join NCT07218809 on ClinicalTrials.gov

7. A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)

   The purpose of this study is to see if propranolol and etodolac along with mind-body resilience training/MBRT and music therapy help participants who are experiencing physiological stress before, during, and after primary debulking surgery/PDS or IDS and also if it's better than the standard-of-car…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT05429970 on ClinicalTrials.gov

8. [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

   This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of [18F]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast can…

   Stage

   Phase 1

   Ages

   18 to 80

   Site

   University of Texas Southwestern Medical Center, Dallas, Texas

   Run by

   Blue Earth Diagnostics

   See if you can join NCT07432633 on ClinicalTrials.gov

9. CT-95 in Advanced Cancers Associated With Mesothelin Expression

   This is a Phase 1a/1b, first-in-human (FIH), open-label, multi-center dose escalation and expansion study of the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of single-agent CT-95 in subjects with advanced (recurrent, unresectable, or metastatic) cancers associated with M…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Context Investigational Site, Denver, Colorado

   Locations

   9 in total

   Run by

   Context Therapeutics Inc.

   See if you can join NCT06756035 on ClinicalTrials.gov

10. Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

    The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9-CAR.B7-H3 T cells) in patients with ovarian cancer that came back after receiving standard therapy for this cancer.…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT06305299 on ClinicalTrials.gov

11. A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer

    This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Site 0264, Aurora, Colorado

    Locations

    24 in total

    Run by

    K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc

    See if you can join NCT04516447 on ClinicalTrials.gov

12. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

    This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic, Phoenix, Arizona

    Locations

    14 in total

    Run by

    858 Therapeutics, Inc.

    See if you can join NCT06395519 on ClinicalTrials.gov

13. A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

    This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer. Th…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    5 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT06469281 on ClinicalTrials.gov

14. CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

    A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Mayo Clinic Hospital, Phoenix, Arizona

    Locations

    66 in total

    Run by

    TORL Biotherapeutics, LLC

    See if you can join NCT06690775 on ClinicalTrials.gov

15. Study of AVZO-021 in Patients With Advanced Solid Tumors

    This study, the first clinical trial of AVZO-021, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and anti-tumor effects of AVZO-021 in patients with advanced solid tumors. AVZO-021 is an oral medication that inhibits cyclin-dependent kinase 2…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Yale Cancer Center, New Haven, Connecticut

    Locations

    13 in total

    Run by

    Avenzo Therapeutics, Inc.

    See if you can join NCT05867251 on ClinicalTrials.gov

16. Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

    The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Moores Cancer Center UC San Diego Health, La Jolla, California

    Locations

    20 in total

    Run by

    Bicara Therapeutics

    See if you can join NCT04429542 on ClinicalTrials.gov

17. Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

    This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced solid malignancies. Patients will be screened and evaluated to determ…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    HonorHealth Research Institute, Scottsdale, Arizona

    Locations

    3 in total

    Run by

    BioEclipse Therapeutics

    See if you can join NCT04282044 on ClinicalTrials.gov